Novato’s UltraGenyx Appoints new Chief Operating Officer
The Novato-based rare drug developer UltraGenyx Pharmaceutical has expanded its leadership team with the appointment of a new chief operating officer. Wladimir (Vlad), M.D., Hogenhuis joins UltraGenyx as COO, from global healthcare company GlaxoSmithKline, where he where he most recently served as Senior Vice President and General Manager, Specialty Franchise.
“Ultragenyx is a company that is making great strides in translating science into therapies that make a meaningful difference in the lives of patients with rare diseases, and I look forward to joining the company at this pivotal time,” said Dr. Hogenhuis.
Dr. Hogenhuis has a Medical Degree Cum Laude from Leiden University in the Netherlands and an MBA degree from the Wharton School of Business.